PROCEPT BioRobotics (PRCT) Is Down 9.2% After Aquablation WATER IV Milestones - What's Changed

PROCEPT BioRobotics recently reported two major milestones in its WATER IV prostate cancer program, completing enrollment in the randomized WATER IV RP trial comparing Aquablation therapy with radical ...

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

Siemens Healthineers, AiM team up; Procept completes study enrollment

Siemens Healthineers’ MRI scanners would guide robotic neurosurgeries performed with AiM’s platform. Elsewhere, Procept ...

Here’s What the Street Thinks About PROCEPT BioRobotics Corporation (PRCT)

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the best robotic surgery stocks to buy. PROCEPT BioRobotics ...
Forbes

PROCEPT BioRobotics

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic ...
The Motley Fool

Why Shares of Procept Biorobotics Were Slumping Thursday

The company continues to grow revenue. It lost $28.5 million in the first quarter. Procept's lead product is a robotic surgery system used to perform prostate procedures. Procept makes the AquaBeam ...
Nasdaq

What Analysts Are Saying About PROCEPT BioRobotics Stock

Throughout the last three months, 7 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of ...